The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...

Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer ...